Fifth Third Wealth Advisors’s Lineage Cell Therapeutics LCTX Stock Holding History

Fifth Third Wealth Advisors’s Portfolio LCTX Stock Details LCTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q3	–	Sell	-20,000	Closed	-$18.1K	–	797
2025 Q2	$18.1K	Hold	20,000	–	–	﹤0.01%	748
2025 Q1	$9.03K	Hold	20,000	–	–	﹤0.01%	705
2024 Q4	$10.1K	Hold	20,000	–	–	﹤0.01%	721
2024 Q3	$18.1K	Hold	20,000	–	–	﹤0.01%	698
2024 Q2	$19.9K	Hold	20,000	–	–	﹤0.01%	666
2024 Q1	$29.6K	Buy	+20,000	New	+$22.7K	﹤0.01%	245

Other funds holding LCTX

Broadwood Capital New York $1.91B AUM 44.39% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Raffles Associates New York $117M AUM 22.1% 1-Year Est. Return

Comerica Bank Dallas, Texas $25.1B AUM 24.68% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

DIG

Dauntless Investment Group Etna, New Hampshire $127M AUM 42.43% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Fifth Third Wealth Advisors's LCTX Position: Q3 2025 in Review

Fifth Third Wealth Advisors sold out of Lineage Cell Therapeutics (LCTX) in Q3 2025, closing a stake of 20,000 shares — an estimated $18.1K sold.

Fifth Third Wealth Advisors first reported a position in LCTX in Q1 2024 and held it in 6 quarters. The position peaked at $29.6K in Q1 2024. 112 funds tracked by Wall St. Rank hold LCTX as of Q3 2025.

Fifth Third Wealth Advisors reported no remaining Lineage Cell Therapeutics position as of Q3 2025 after selling out during the quarter.
Fifth Third Wealth Advisors sold 20,000 Lineage Cell Therapeutics shares in Q3 2025, an estimated $18.1K.
Fifth Third Wealth Advisors first reported a position in Lineage Cell Therapeutics in Q1 2024 and held it in 6 quarters.
Fifth Third Wealth Advisors's Lineage Cell Therapeutics position peaked at $29.6K in Q1 2024.
112 funds tracked by Wall St. Rank held Lineage Cell Therapeutics as of Q3 2025.

Based on Fifth Third Wealth Advisors's 13F filing for Q3 2025, filed 21 Oct 2025.